INTRODUCTION {#h0.0}
============

Horizontal gene transfer is one of the most powerful forces in bacterial evolution. The transformative potential of this process is perhaps best exemplified by the acquisition of antimicrobial resistance determinants: in a single genetic event, an antimicrobial-susceptible bacterium can acquire a complex suite of resistance determinants and become resistant to multiple antimicrobials. Thus, frequent horizontal transfer between different strains can potentially drive the spread of antibiotic resistance within the bacterial population, without any change in the distribution of strains. However, when virulent bacterial clones acquire such elements, they can emerge rapidly within the population through clonal expansion and thereby gain local or even global predominance ([@B1]--[@B3]). Quantifying the relative contribution of horizontal (gene transfer) and vertical (clonal expansion) mechanisms to the emergence of multidrug-resistant bacterial pathogens will provide important insights into the evolution of these pathogens and inform novel intervention strategies.

In 2008, a previously unrecognized *Escherichia coli* clonal group, sequence type 131 (ST131), was identified in nine countries, spanning three continents ([@B4], [@B5]). Today, ST131 is the dominant extraintestinal pathogenic *E. coli* (ExPEC) strain worldwide, but retrospective analyses suggest that the pandemic emergence of ST131 took place over a period of fewer than 10 years ([@B6], [@B7]). ST131 is part of the virulent phylogenetic group B2 and has been reported to cause a wide range of infections, including meningitis, osteomyelitis, myositis, epididymo-orchitis, and peritonitis ([@B6], [@B8]--[@B10]). However, ST131 is most commonly associated with urinary tract infection (UTI) and is a major etiologic agent of bladder infections, kidney infections, and urosepsis in the United States and internationally ([@B11]--[@B14]). Population genetics analysis of ST131 isolates indicated that the recent epidemic spread of this group is driven by descendants of a single strain, named subclone *H*30, that differ from the members of other, less prevalent ST131 subclones by carriage of *fimH*30, an allele of the gene encoding the mannose-specific type 1 fimbrial adhesin, FimH ([@B15]).

Over the last decade, the emergence of multidrug-resistant ExPEC strains has made UTI treatment more problematic, leading to discordant antimicrobial therapy and increased morbidity and mortality ([@B16]--[@B19]). This increase in multidrug-resistant UTIs has in large part been due to the rapid rise in prevalence of ExPEC strains---particularly from ST131---harboring determinants for extended-spectrum β-lactamases (ESBLs) and resistance to trimethoprim-sulfamethoxazole and fluoroquinolones (FQ) ([@B16], [@B20]--[@B27]).

The CTX-M-15 β-lactamase is the dominant ESBL in ST131 and is increasingly found in isolates causing both UTI and bacteremia ([@B13], [@B28]--[@B31]). The CTX-M gene phylogeny suggests that these enzymes arose through mobilization of chromosomal β-lactamase (*bla*) genes from the gut commensal organism *Kluyvera* ([@B32]). A number of CTX-M enzymes have risen to prevalence since the 1990s, with a new CTX-M type frequently appearing in multiple distant countries simultaneously, suggesting independent transfer events ([@B33]). This, together with the substantial diversity in transferable resistance elements in ST131, has led some to conclude that horizontal transfer must be the dominant mechanism whereby ESBLs have gained prominence among strains of the ST131 clone ([@B7], [@B34], [@B35]). However, other evidence suggests that clonal expansion contributes significantly to the spread of antimicrobial resistance within *E. coli* ([@B36]--[@B39]).

Until recently, our knowledge of the epidemiology and dispersal of bacterial strains, including of ST131 origin, has been based largely on multilocus sequence typing (MLST), which has limited resolution at the subclone level, and on pulsed-field gel electrophoresis (PFGE) analysis, which is highly vulnerable to distortions from horizontal gene transfer events and subjective interpretation. In the current study, we used whole-genome single-nucleotide polymorphism (SNP) analysis to reconstruct the ST131 phylogeny and then overlaid resistance determinants and phenotypic susceptibility on this phylogeny to elucidate the evolutionary history of fluoroquinolone resistance and ESBL production within this prominent pathogen.

RESULTS {#h1}
=======

PFGE analyses. {#h1.1}
--------------

A collection of 524 ST131 isolates cultured from humans and animals between 1967 and 2011 was analyzed using PFGE, which yielded a complex dendrogram ([Fig. 1A](#fig1){ref-type="fig"}). Within the PFGE-based dendrogram, the isolates that were fluoroquinolone resistant and/or *bla*~CTX-M-15~ positive, although exhibiting some clustering, were intermingled extensively with those that were fluoroquinolone susceptible and/or *bla*~CTX-M-15~ negative. As such, the PFGE analysis supported previous reports suggesting frequent horizontal acquisition of fluoroquinolone resistance determinants and *bla*~CTX-M-15~ among different ST131 subclones.

![PFGE dendrogram and whole-genome SNP-based phylogeny of *E. coli* ST131. (A) PFGE-based dendrogram of *E. coli* ST131 isolates (*n* = 524), as inferred within BioNumerics according to the unweighted pair group method based on Dice similarity coefficients. (B) Whole-genome SNP-based phylogeny of selected ST131 isolates (*n* = 105) and the NA114 reference genome. SNPs were identified from genomic regions equivalent to approximately 44.7% of the reference genome that was shared among all isolates and sequenced at ≥10× coverage. Analysis of these shared genomic regions revealed 2,531 parsimony-informative and 4,000 total SNPs from the core genome (excluding horizontally acquired regions) that were used to construct the phylogeny presented here. Homoplasy index (HI) = 0.012. The purple block highlights the *H*30 subclone.](mbo0061316830001){#fig1}

Whole-genome SNP-based phylogenetic reconstruction of ST131. {#h1.2}
------------------------------------------------------------

From the total collection that underwent PFGE analysis, 105 ST131 isolates were systematically selected for genome sequencing according to prespecified criteria that emphasized diversity of genetic backgrounds according to PFGE. The 105 isolates, which derived from five countries and 23 states and provinces in Canada and the United States, included 22 CTX-M-15-producing isolates, which were widely distributed across the PFGE dendrogram ([Fig. 1A](#fig1){ref-type="fig"}).

Genomic comparisons identified SNP loci that were present in all isolates and, therefore, informative for phylogenetic reconstruction. The first phylogenetic tree included non-ST131 strain AA86 (group B2; ST1876) ([@B40]) as an outgroup, to root the tree and to identify the basal clones within the ST131 phylogeny (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material). Next, strain AA86 was excluded, and a new SNP matrix and phylogenetic tree were generated (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material). Since (distant) strain AA86 lacks some of the genomic regions found within the ST131 clone, exclusion of AA86 increased the number of shared genomic regions in the sequence alignment and, therefore, increased the number of informative SNPs with which to resolve the ST131 phylogeny.

The homoplasy index (HI) for these two initial trees (see [Fig. S1 and S2](#figS1 figS2){ref-type="supplementary-material"}) was exceedingly high (\>0.33), indicating substantial recombination. Phylogenetic reconstructions that include genomic regions acquired by horizontal gene transfer will not accurately represent the evolutionary history of clonal organisms. However, such phylogenies can be used to identify the regions acquired horizontally. This was accomplished here by mapping to the reference genome the HI values for individual SNPs, which revealed four large recombinant regions representing nearly 31% of the genome.

Exclusion of SNPs from the four horizontally acquired regions resulted in trees with minimal homoplasy (homoplasy index \[HI\] = 0.012) (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material), suggestive of highly accurate phylogenies ([@B41]). [Figure 1B](#fig1){ref-type="fig"} shows the resultant whole-genome SNP phylogeny for the 105 ST131 isolates, plus the strain NA114 reference ST131 genome ([@B42]).

Whole-genome-based clustering of resistant subclones. {#h1.3}
-----------------------------------------------------

The whole-genome SNP-based phylogeny showed distinct clustering of strains carrying specific *fimH* alleles ([Fig. 1B](#fig1){ref-type="fig"}), as well as *gyrA* and *parC* alleles and O type (see [Dataset S1](#DS1){ref-type="supplementary-material"} and [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material). In particular, strains carrying the *fimH*30 allele clustered as a single low-diversity clade, designated *H*30, which included 58 (95%) of the 61 fluoroquinolone-resistant isolates. Moreover, nearly all of the CTX-M-15-producing isolates, despite appearing to have diverse genetic backgrounds according to the PFGE-based dendrogram ([Fig. 1A](#fig1){ref-type="fig"}), collapsed into a distinct subclade within the *H*30 clade ([Fig. 1B](#fig1){ref-type="fig"}).

To further resolve the evolutionary history of the *H*30 subclone, genomic sequences from the 64 *H*30 isolates and their three nearest neighbors were analyzed separately from the rest of the isolates ([Fig. 2](#fig2){ref-type="fig"}). Aligning these sequences to the finished NA114 reference genome increased the number of shared nucleotides and revealed additional informative SNPs that were used to generate the high-resolution and highly accurate (HI = 0.000) phylogenetic tree shown in [Fig. 2](#fig2){ref-type="fig"}. This tree suggested that acquisition of the *fimH*30 allele preceded the acquisition of fluoroquinolone resistance by a single ancestor within the *H*30 subclone, which was followed by a large clonal expansion of fluoroquinolone-resistant *H*30 strains. To distinguish the clonally related fluoroquinolone-resistant *H*30 isolates from the ancestral fluoroquinolone-susceptible *H*30 isolates, the resistant subclone within *H*30 was designated *H*30-R.

![High-resolution phylogenetic analysis of the emergence of fluoroquinolone resistance and CTX-M-15 production. Approximately 51.8% of the reference genome was shared among all isolates and sequenced at ≥10× coverage. Analysis of these shared genomic regions revealed 72 parsimony-informative SNPs and 771 total SNPs from the core genome (excluding horizontally acquired regions) that were used to construct the phylogeny presented here. Homoplasy index (HI) = 0.000. The colored blocks highlight the three nested ST131 subclones, *H*30 (purple), *H*30-R (blue), *H*30-Rx (yellow).](mbo0061316830002){#fig2}

In this high-resolution phylogeny, 20 (91%) of the 22 ST131 isolates that carried *bla*~CTX-M-15~---including isolates from Australia, South Korea, Portugal, Canada, and the United States---formed a distinct, single-ancestor subclone within *H*30-R. Because of its more extensive resistance characteristics, this *bla*~CTX-M-15~-associated subclone was designated *H*30-Rx ([Fig. 2](#fig2){ref-type="fig"}). Three canonical SNPs distinguished *H*30-Rx from the rest of *H*30-R with 100% fidelity.

Genomic location of the CTX-M-15 element. {#h1.4}
-----------------------------------------

Multiple previous studies have reported that *bla*~CTX-M-15~ is positioned on a conjugative IncFII-type plasmid as part of a Tn*3*-like *ISEcp1*-*bla*~CTX-M-15~-orf477 mobile element. Here, we performed an *in silico* analysis to characterize the structure and genomic location of the CTX-M-15 mobile element among the 22 *bla*~CTX-M-15~-positive ST131 isolates. In each instance, *bla*~CTX-M-15~ was part of a typical Tn*3*-like *ISEcp1*-*bla*~CTX-M-15~-orf477 transposable element. While no SNPs were identified among the different CTX-M-15 elements, the regions flanking *bla*~CTX-M-15~ were frequently degraded by insertion/deletion (not shown). The Illumina short-read sequences were sufficient to reliably identify the element's insertion site for all but three of the 22 CTX-M-15-positive isolates sequenced in the current study ([Table 1](#tab1){ref-type="table"}). The insertion site varied among the isolates: 13 carried a single copy on an IncFII-type plasmid, four carried a single copy on the chromosome, and two carried one copy on the chromosome and another copy on an IncFII-type plasmid ([Table 1](#tab1){ref-type="table"}). Moreover, among the strains with a chromosomally located element, five distinct chromosomal insertion sites were identified; only two strains, JJ1886 and JJ1887, which are the nearest neighbors in the SNP phylogeny ([Fig. 2](#fig2){ref-type="fig"}), carried the element in the same chromosomal location ([Table 1](#tab1){ref-type="table"}).

###### 

CTX-M-15 element locations among the 22 *Escherichia coli* ST131 isolates

  --------------------------------------------------------------------------------------------------------
  Isolate\   Subclone              Genomic location^[*a*](#ngtab1.1)^   Chromosomal\
  name                                                                  insertion site^[*b*](#ngtab1.2)^
  ---------- --------------------- ------------------------------------ ----------------------------------
  JJ2444     *H*30-Rx              Chromosome                           2,037,134

  JJ2038     *H*30-Rx              Chromosome                           2,127,735

  JJ1886     *H*30-Rx              Chromosome                           1,473,842

  JJ1887     *H*30-Rx              Chromosome                           1,473,842

  JJ2434     *H*30-Rx              Plasmid and chromosome               4,493,369

  MH5800     *H*30-Rx              Plasmid and chromosome               4,191,808

  JJ2547     *H*30-Rx              Plasmid                              NA

  JJ2555     *H*30-Rx              Plasmid                              NA

  JJ2008     *H*30-Rx              Plasmid                              NA

  JJ1914     *H*30-Rx              Plasmid                              NA

  JJ2441     *H*30-Rx              Plasmid                              NA

  JJ2489     *H*30-Rx              Plasmid                              NA

  JJ2657     *H*30-Rx              Plasmid                              NA

  JJ2643     *H*30-Rx              Plasmid                              NA

  U004       *H*30-Rx              Plasmid                              NA

  CD358      *H*30-Rx              Plasmid                              NA

  NA1114     *H*30-Rx              Plasmid^[*c*](#ngtab1.3)^            NA

  MH17102    *H*30-Rx              Undetermined                         NA

  QUC02      *H*30-Rx              Undetermined                         NA

  KN1604     *H*30-Rx              Undetermined                         NA

  JJ2244     *H*30, non-*H*30-Rx   Plasmid                              NA

  JJ2591     Non-*H*30             Plasmid                              NA
  --------------------------------------------------------------------------------------------------------

Marked as undetermined if the *in silico* analyses provided equivocal results.

Chromosomal location based on the JJ1886 closed genome. NA, not applicable.

Reported previously.

Association of ESBL production and *bla*~CTX-M-15~ with the *H*30-Rx ST131 subclone. {#h1.5}
------------------------------------------------------------------------------------

Because most of the isolates in the phylogenetic trees were of historic (i.e., pre-2009) origin, we assessed the generalizability of the observed association of the *H*30-Rx subclone with ESBL production and *bla*~CTX-M-15~ by analyzing more recent clinical isolates, i.e., from 2011 to 2013. For this, a total of 261 ST131 isolates from Seattle, WA, Minneapolis, MN, and Münster, Germany, were assessed for *fimH* allele type, *H*30-Rx subclone membership, ESBL production, and possession of *bla*~CTX-M-15~ ([Table 2](#tab2){ref-type="table"}).

###### 

Association of ST131 subclones with resistance traits among 261 recent clinical isolates of *Escherichia coli* ST131 from the United States and Germany

  Resistance trait   Prevalence of resistance trait, no. (%)                               
  ------------------ ----------------------------------------- ------- ------- ----------- ----------------------------
  FQ resistant       163 (62)                                  0 (0)   0 (0)   119 (100)   44 (100)^[*a*](#ngtab2.1)^
  ESBL               45 (17)                                   3 (3)   1 (9)   7 (6)       34 (77)^[*b*](#ngtab2.2)^
  *bla*~CTX-M-15~    39 (15)                                   3 (7)   1 (9)   2 (2)       33 (75)^[*c*](#ngtab2.3)^

For the fluoroquinolone (FQ)-resistant fraction, *H*30-Rx compared to other ST131 isolates, *P* \< 0.001 (Fisher's exact test \[FET\]).

For prevalence of extended-spectrum β-lactamase (ESBL) production, *H*30-Rx compared to other ST131 isolates, *P* \< 0.001 (FET).

For prevalence of *bla*~CTX-M-15~, *H*30-Rx compared to other ST131 isolates, *P* \< 0.001 (FET).

Among the 261 recent ST131 isolates, 174 (67%) belonged to the *H*30 subclone, whereas the remaining 87 (33%) carried one of several other ST131-associated *fimH* alleles, as described recently ([@B15]). Among the 174 *H*30 isolates, the 163 (94%) that were fluoroquinolone resistant were defined as *H*30-R. Detection of *H*30-Rx-specific SNPs showed that *H*30-Rx comprised 44 (27%) of 163 *H*30-R strains ([Table 2](#tab2){ref-type="table"}).

Among the 44 *H*30-Rx isolates, 34 (77%) were ESBL producing, and 33 of these carried *bla*~CTX-M-15~. This was very similar to the 74% carriage of *bla*~CTX-M-15~ observed among the genome-sequenced historic *H*30-Rx isolates ([Fig. 2](#fig2){ref-type="fig"}) but significantly higher than the low prevalence of either ESBL production or *bla*~CTX-M-15~ carriage observed among the recent non-*H*30 ST131 isolates (3% for each trait), *H*30 but not *H*30-R isolates (9% for each trait), and *H*30-R but not *H*30-Rx isolates (6% and 2% for the two traits, respectively) ([Table 2](#tab2){ref-type="table"}). Thus, *bla*~CTX-M-15~ accounted for nearly all ESBL-producing isolates within the *H*30-Rx subclone; conversely, within ST131 overall, the *H*30-Rx subclone accounted for the vast majority of ESBL production and, especially, *bla*~CTX-M-15~ carriage. Moreover, this tight association between *H*30-Rx and *bla*~CTX-M-15~ held true across the different laboratories that supplied the recent clinical isolates (data not shown).

Demographic, geographic, and clinical prevalence of *H*30-Rx. {#h1.6}
-------------------------------------------------------------

We also assessed the relative prevalence of the *H*30-R and *H*30-Rx subclones within the total ST131 population in relation to patient population and locale by comparing urine isolates from Group Health Cooperative in Seattle, WA, which serves an almost exclusively outpatient population, with urine isolates from hospital laboratories in the United States and Germany that serve mixed inpatient and outpatient populations. The relative prevalence of *H*30-Rx was highest among the German Hospital isolates (where it exceeded the prevalence even of other *H*30-R isolates), intermediate among United States-based hospital isolates, and lowest among the Group Health outpatient isolates ([Table 3](#tab3){ref-type="table"}).

###### 

Prevalence of ST131 subclones in relation to source population among 261 recent clinical isolates of *Escherichia coli* ST131 from the United States and Germany

  Source population          Total no. of ST131 isolates   ST131 subclones, no. (%)                     
  -------------------------- ----------------------------- -------------------------- ------- --------- --------------------------------------------
  United States ambulatory   86                            35 (41)                    3 (4)   42 (49)   6 (7)^[*a*](#ngtab3.1),[*b*](#ngtab3.2)^
  United States hospital     120                           32 (27)                    4 (3)   64 (53)   20 (17)^[*a*](#ngtab3.1),[*c*](#ngtab3.3)^
  German hospital            55                            20 (36)                    4 (7)   13 (24)   18 (33)^[*b*](#ngtab3.2),[*c*](#ngtab3.3)^

For prevalence of *H*30-Rx, United States ambulatory compared to United States hospital isolates, *P* = 0.054 (FET).

For prevalence of *H*30-Rx, United States ambulatory compared to German hospital isolates, *P* \< 0.001 (FET).

For prevalence of *H*30-Rx, United States hospital compared to German hospital isolates, *P* = 0.03 (FET).

Data regarding presence/absence of clinically diagnosed sepsis were available for 162 of the recent United States ST131 clinical isolates, among which 12 source patients (7%) overall were diagnosed with sepsis ([Table 4](#tab4){ref-type="table"}), a value similar to the 5.2% overall prevalence of diagnosed sepsis among the 1,133 extraintestinal clinical isolates from which the 162 ST131 strains were derived (*P* = 0.26) ([@B15]). However, sepsis was diagnosed in 28% of the patients with an *H*30-Rx isolate ([Table 4](#tab4){ref-type="table"}), a significantly greater proportion than among patients with a non-*H*30-Rx, *H*30-R isolate (6%; *P* = 0.02), a non-*H*30, ST131 isolate (4%; *P* = 0.01), any non-*H*30-Rx, ST131 isolate (5%; *P* = 0.005), or a non-ST131 isolate (5.6%; *P* = 0.003). For *H*30-Rx isolates compared to other ST131 isolates, the relative risk of associated sepsis was 7.5 (95% confidence interval, 2.3 to 23.8).

###### 

Association of ST131 subclones with clinical sepsis among 162 recent clinical isolates of *Escherichia coli* ST131 from the United States

  Clinical presentation   No. (%) of isolates with associated clinical presentation                                                                                 
  ----------------------- ----------------------------------------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  No sepsis               150 (92.6)                                                  54 (96)                   6 (100)                   77 (94)                   13 (72)
  Sepsis                  12 (7.4)                                                    2 (4)^[*a*](#ngtab4.1)^   0 (0)^[*b*](#ngtab4.2)^   5 (6)^[*c*](#ngtab4.3)^   5 (28)^*a*,*b*,*c*,*d*^

For prevalence of sepsis, *H*30-Rx compared to non-*H*30, *P* = 0.008 (FET).

For prevalence of sepsis, *H*30-Rx compared to non-*H*30-R (*H*30), *P* = 0.28 (FET).

For prevalence of sepsis, *H*30-Rx compared to non-*H*30-Rx (*H*30-R), *P* = 0.016 (FET).

^*d*^ For prevalence of sepsis, *H*30-Rx compared to all other ST131 (7/144, 5%), *P* = 0.005 (FET).

DISCUSSION {#h2}
==========

The results of this study provide compelling evidence that clonal expansion is the dominant mechanism for the proliferation of both CTX-M-15 production and fluoroquinolone resistance in *E. coli* ST131. Past studies have shown that the determinants for both of these traits can be acquired through horizontal gene transfer or, in the case of fluoroquinolone resistance, independent mutation ([@B15]). However, the whole-genome SNP-based phylogenies presented here show that almost all of the fluoroquinolone-resistant ST131 isolates belong to a distinct subclone, *H*30-R, which was derived from a single common ancestor carrying the *fimH*30 allele (i.e., part of the *H*30 subclone). Likewise, 91% of the CTX-M-15-producing isolates form another distinct subclone, *H*30-Rx, which was derived from a single common ancestor within the *H*30-R subclone. These nested subclones form a Russian-doll-like configuration, within which each subsequent lineage is more extensively resistant than the former.

The nearly exclusive confinement of the CTX-M-15 element to the *H*30-Rx subclone was in striking contrast to this element's promiscuity within the ST131 genome. We identified *H*30-Rx isolates with a copy of the element on the chromosome, on an IncFII-type plasmid, and, in some instances, on both the chromosome and a plasmid. Moreover, among those isolates with a chromosomal CTX-M-15 element, the element was inserted in five different locations. Notably, the only two isolates with identical chromosomal insertion sites were recovered from epidemiologically linked adult siblings who both suffered from UTIs of varying severity and were suspected of sharing the same ST131 strain ([@B43]), as supported here by the close proximity of these isolates in the high-resolution *H*30 phylogenetic tree ([Fig. 2](#fig2){ref-type="fig"}). Among the 22 CTX-M-15-producing strains, the CTX-M-15 elements exhibited no SNPs and, therefore, no phylogenetic signal that could be compared with the host strain phylogeny.

One cannot exclude the possibility that chromosomal and even some plasmid-borne CTX-M-15 elements were acquired horizontally by *H*30-RX on multiple occasions. However, three lines of evidence suggest that within *H*30-Rx, the chromosomally encoded CTX-M-15 is the result of repeated intragenomic mobilization of the plasmid-located Tn*3*-like *ISEcp1*-*bla*~CTX-M-15~-orf477 element, rather than independent horizontal acquisition events. First, the sequence identity of the CTX-M-15 elements suggests that they represent copies of the same recently derived genetic element. Second, the plasmid location is the most common among *H*30-Rx isolates. Third, some strains with chromosomally encoded CTX-M-15 (e.g., JJ1886 and JJ1887) also maintain an IncFII-type plasmid, albeit missing the CTX-M-15 element, consistent with the CTX-M-15 element having moved from the plasmid to the chromosome.

The exact evolutionary history of CTX-M-15 acquisition in *H*30-Rx also remains to be elucidated. It is possible that *H*30-Rx was founded by an ancestor that acquired CTX-M-15 on an *incF*-type plasmid, which expanded and differentiated along with the subclone. Under this model, the CTX-M-15-negative *H*30-Rx isolates would represent independent gene loss events. An alternative explanation is that the *H*30-Rx subclone was founded by a CTX-M-15-negative ancestor and partially expanded before becoming extensively cephalosporin resistant later, through horizontal acquisition of the CTX-M-15 element. Indeed, this subclone may be under differential third-generation cephalosporin selection due to its enhanced virulence, which might result in its being exposed to aggressive antimicrobial therapy more commonly than other *E. coli* strains. Further investigation, including total chromosome and plasmid closure, could clarify the most probable mechanism for the association between *H*30-Rx and CTX-M-15. Interestingly, however, the *bla*~CTX-M-15~-positive, FQ-resistant JJ2244 strain, which occupies a phylogenetic outgroup position relative to both *H*30-R and *H*30-Rx (see [Fig. 2](#fig2){ref-type="fig"}), likely represents an independently emerged multidrug-resistant clonal lineage within the *H*30 subclone. Indeed, this strain not only lacks all canonical *H*30-Rx SNPs but also has a distinct, recombinant FQ resistance-conferring *gyrA-parC* allele combination (i.e., 1AB/4A), compared with that present in *H*30-R (i.e., 1AB/1aAB).

The results of this whole-genome SNP-based analysis depicted a considerably different evolutionary history for ST131 from that derived from PFGE analysis. Our use of an iterative approach to identify and exclude SNPs from recombinant regions elucidated an evolutionary path marked by clonal expansions rather than frequent lateral gene acquisitions. This underscores one of the major advantages of a whole-genome SNP-based approach relative to PFGE. Although PFGE likewise uses signatures from throughout the genome, it is highly vulnerable to phylogenetic distortions from horizontal gene transfer, which can lead to false assumptions about the evolutionary history of an organism ([@B44]), and from subjective interpretation of banding patterns and the (often invalid) presumption that similarly migrating bands represent the same chromosomal region.

The biological basis for the proliferation of *H*30-R and *H*30-Rx remains unclear. It is possible that antimicrobial resistance, the seemingly obvious explanation, is not the sole selective characteristic leading to the successive proliferation of *H*30-R and *H*30-Rx from within the *H*30 subclone. This is suggested by the fact that certain non-*H*30 ST131 isolates were identified that possessed the same phenotypic resistance traits without having reached a comparable level of success as *H*30-Rx. Increased virulence, as suggested by the significant association between *H*30-Rx and sepsis, could be a factor contributing to the success of this important subclone. Further investigations, including detailed comparative genomic, epidemiological, and functional studies, are needed to determine the basis for the success of *H*30-R and the strong association of *H*30-Rx with sepsis.

Regardless of mechanisms, the association of *H*30-Rx with sepsis, its broad multidrug resistance profile, and its rapid expansion and geographic dispersal warrant attention from the public health and clinical communities. Although continued accumulation of antibiotic resistance determinants may limit therapeutic options in the future, the clonal nature of *H*30-Rx may facilitate effective control strategies involving vaccines or transmission prevention.

MATERIALS AND METHODS {#h3}
=====================

Isolates and patients. {#h3.1}
----------------------

The molecular epidemiological analyses used a large collection (*n* = 1,908) of recent, consecutive, single-patient *E. coli* isolates from 6 clinical microbiology laboratories in the United States and Germany. The United States isolates (*n* = 1,518) were recovered in 2010 and 2011 from 5 locations, including Group Health Cooperative, Harborview Medical Center, Seattle Children's Hospital, and University of Washington Medical Center (all in Seattle, WA) and the Veterans Affairs Medical Center in Minneapolis, MN, as described previously ([@B15]). The German isolates (*n* = 390) were recovered in 2012 at the University Hospital in Münster, Germany. All isolates underwent *fumC-fimH* (CH) clonotyping ([@B45]) to identify ST131 and its constituent CH clonotypes (i.e., *fimH*-specific subclones, including *H*30) and were assessed for ESBL production by disk diffusion as specified by the Clinical and Laboratory Standards Institute. Medical record data regarding presence of clinically diagnosed sepsis at the time of sample collection or during the subsequent 30 days were available for 1,133 (75%) of the 2010-2011 United States isolates. Each center's institutional review board approved the study protocol.

PFGE analysis. {#h3.2}
--------------

The 524 historical and recent ST131 isolates were subjected to standardized XbaI PFGE analysis, as described previously ([@B46]). The dendrogram was inferred within BioNumerics (Applied Maths) according to the unweighted pair group method based on Dice similarity coefficients.

Strain selection. {#h3.3}
-----------------

Selection of ST131 isolates for genome sequencing was done in successive phases. First, to sample the breadth of phylogenetic diversity within the ST (to the extent that this is reflected in PFGE profiles), 20 isolates were selected to represent widely distributed clusters within a PFGE profile dendrogram based on a published collection of 524 historical and recent ST131 isolates from diverse locales, years of isolation, and hosts ([Fig. 1A](#fig1){ref-type="fig"}). In selecting the representative isolate(s) for a given PFGE cluster, priority was given to (i) most recent year of isolation, (ii) human host, and (iii) fluoroquinolone resistance. Next, 28 additional isolates were selected from these same PFGE clusters based on (i) proximity in the dendrogram to the initially selected (index) isolate and (ii) differences from the index isolate with respect to host and/or fluoroquinolone phenotype. Subsequently, an additional 60 isolates were selected from both this initial collection and a large collection of recent human clinical ST131 isolates from Seattle, WA, and Minneapolis, MN, that had undergone sequence analysis of *gyrA*, *parC*, and *fimH* (to define subclones within ST131) and PFGE analysis. Here, selection criteria included (i) distinctive *gyrA*, *parC*, and/or *fimH* alleles, or combinations thereof, (ii) outliers with respect to fluoroquinolone phenotype, in comparison with other isolates sharing the same PFGE type or *gyrA-parC-fimH* allele combination, and (iii) distinctive host species, clinical presentations (e.g., published case report isolates), specimen types (e.g., food or environmental), or dates of isolation (e.g., oldest known and oldest published ST131 isolates). Of the 108 total selected isolates, four isolates were subsequently excluded due to questionable authenticity, leaving 104 isolates for genome sequencing.

Genome sequencing. {#h3.4}
------------------

DNA samples were prepared for multiplexed, paired-end sequencing on an Illumina Genome Analyzer IIx (Illumina, Inc., San Diego, CA). For each isolate, 1 to 5 µg DNA in 200 µl was sheared in a 96-well plate with the SonicMAN (part no. SCM1000-3; Matrical BioScience, Spokane, WA) to a size range of 200 to 1,000 bp, with the majority of material at ca. 600 bp, using the following parameters: prechill, 0°C for 75 s; cycles, 20; sonication, 10 s; power, 100%; lid chill, 0°C for 75 s; plate chill, 0°C for 10 s; postchill, 0°C for 75 s. The sheared DNA was purified using the QIAquick PCR purification kit (catalogue no. 28106; Qiagen, Valencia, CA). The enzymatic processing (end repair, phosphorylation, A tailing, and adaptor ligation) of the DNA followed the guidelines described in the Illumina protocol ("Preparing Samples for Multiplexed Paired-End Sequencing," catalogue no. PE-930-1002, part no. 1005361). The enzymes for processing were obtained from New England Biolabs (catalogue no. E6000L; New England Biolabs, Ipswich, MA), and the oligonucleotides and adaptors were obtained from Illumina (catalogue no. PE-400-1001).

After ligation of the adaptors, the DNA was run on a 2% agarose gel for 2 h, after which a gel slice containing 500- to 600-bp fragments of each DNA sample was isolated and purified using the QIAquick gel extraction kit (catalogue no. 28706; Qiagen, Valencia, CA). Individual libraries were quantified by quantitative PCR on an ABI 7900HT (part no. 4329001; Life Technologies Corporation, Carlsbad, CA) in triplicate at two concentrations, 1:1,000 and 1:2,000, using the Kapa library quantification kit (part no. KK4832 or KK4835; Kapa Biosystems, Woburn, MA). Based on the individual library concentrations, equimolar pools of no more than 12 indexed *E. coli* libraries were prepared at a concentration of at least 1 nM using 10 mM Tris-HCl (pH 8.0) and 0.05% Tween 20. To ensure accurate loading onto the flow cell, the same quantification method was used to quantify the final pools. The pooled paired-end libraries were sequenced on an Illumina Genome Analyzer IIx to a read length of at least 76 bp.

The genomes were sequenced at an average depth of 60.93× (standard deviation \[SD\] = 31.66, using the 4,971,461-base NA114 chromosome as a reference). An average of 4,654,457.54 bases (SD = 385,629.23) were sequenced at ≥10× coverage.

Identification of SNPs. {#h3.5}
-----------------------

Illumina whole-genome sequence data sets were aligned against the chromosome of a published ST131 reference genome (strain NA114; GenBank accession no. CP002797) ([@B42]) using the short-read alignment component of the Burrows-Wheeler Aligner. Each alignment was analyzed for SNPs using SolSNP, a Java-based DNA variant-calling tool for next-generation sequencing alignment data. SolSNP uses a modified Kolmogorov-Smirnov statistic and data filtering to call variants on high-coverage, aligned genomes (<http://sourceforge.net/projects/solsnp/>). To avoid false calls due to sequencing errors, SNP loci were excluded if they did not meet a minimum coverage of 10× and if the variant was present in \<90% of the base calls for that position. SNP calls were combined for all of the sequenced genomes such that, for the locus to be included in the final SNP matrix, it had to be present in all of the genomes. SNPs falling in the duplicated regions on the reference genome were discarded.

Phylogenetic analysis. {#h3.6}
----------------------

Phylogenetic trees were generated using the maximum-parsimony method in PAUP version 4.0b10. Using prior knowledge about near neighbors, a published *E. coli* strain belonging to the phylogenetic group B2 genome (strain AA86; GenBank accession no. AFET00000000) was selected as an outgroup to root the ST131 whole-genome sequence tree ([@B45]). ST131 isolates in the clade nearest to this bifurcation point were used to root subsequent trees.

The homoplasy index (HI) was calculated in PAUP using the formula HI = 1 − CI, where CI is the consistency index. CI serves to measure the relative amount of homoplasy in a cladogram, as assessed by the level of difficulty in fitting SNP alleles to a given tree. The CI is calculated using the formula CI = *m*/*s*, where *m* is the total number of expected character changes and *s* is the actual number of changes that occur in the tree.

Detection of *H*30-Rx-specific SNPs. {#h3.7}
------------------------------------

Two SNPs that differentiate the CTX-M-15-associated subclone (*H*30-Rx) within the *H*30-R subclone from the rest of the *H*30 subclone were interrogated using Sanger sequencing. SNP-200 was detected as a C-to-T transition at position 299 of the 460-bp PCR product generated using forward primer 5′ GACACCATGCGTTTTGCTTC 3′ and reverse primer 5′ TCGTACCGGCAACAATTGAC 3′. SNP-264 was detected as a G-to-A transition at position 287 of the 462-bp PCR product generated using forward primer 5′ GTGGCGATTTCACGCTGTTA 3′ and reverse primer 5′ TATCCAGCACGTTCCAGGTG 3′. Isolates that tested positive for both SNPs were regarded as members of the *H*30-Rx subclone.

PCR-based detection of *bla*~CTX-M-15~. {#h3.8}
---------------------------------------

The CTX-M-15-encoding gene *bla*~CTX-M-15~ was detected by PCR using SNP-specific forward primer 5′ ATAAAACCGGCAGCGGTGG 3′ and universal reverse primer 5′ GAATTTTGACGATCGGGG 3′ ([@B47]). PCR conditions were 10 min of denaturation at 95°C, 33 cycles of 30 s at 94°C, and 30 s at 67°C, followed by 7 min at 72°C elongation. The *bla*~CTX-M-15~-specific 483-bp PCR product was detected by agarose gel electrophoresis

Location of CTX-M-15-encoding mobile element. {#h3.9}
---------------------------------------------

Illumina short reads were aligned to the closed chromosome of JJ1886 (CP006784, CP006785, CP006786, CP006787, CP006788, and CP006789) ([@B54]) and the pEC_L8 closed plasmid sequence using BWA-MEM ([@B48]) version 0.7.5a-r405 with the default settings for paired reads. Alignments were analyzed using the IGV tool ([@B49], [@B50]). The location of the conserved CTX-M-15 element (*ISEcp1*-*bla*~CTX-M-15~-orf477) was then inferred based on the sequence alignments. Close attention was paid to the boundaries of the element, since any unmapped or incorrectly mapped pairs or pairs with insertions or deletions provided clues as to the genomic location and possible rearrangements. Putative duplications were noted if the depth of coverage around the element was substantially higher than the flanking regions. Illumina short reads were also assembled with the Mira assembler ([@B51]). The contigs were aligned with Mauve ([@B52]) against JJ1886 and pEC_L8 to identify any chromosomal rearrangement in the contigs carrying the CTX-M-15 element.

*fimH* and *gyrA-parC* allele assignments. {#h3.10}
------------------------------------------

Sequenced isolates were assembled using VelvetOptimiser (version 2.2.2) and Velvet ([@B53]). All *fimH*, *gyrA*, and *parC* sequences were compared to an in-house sequence library using nucleotide-nucleotide BLAST (version 2.2.25+). Sequence similarity matches were determined using thresholds of 100% nucleotide identity and 100% coverage of the query sequence length. Allele designations were assigned based on an in-house nomenclature for the *gyrA*-*parC* combination and *fimH*.

Statistical methods. {#h3.11}
--------------------

Comparisons of proportions were tested using Fisher's exact test or a chi-square test (two tailed), with *P* values of \<0.05 as the criterion for significance.

Accession number. {#h3.12}
-----------------

All Illumina sequences were deposited into the NCBI SRA (<http://www.ncbi.nlm.nih.gov/sra>), study accession number SRP027327.

SUPPLEMENTAL MATERIAL {#h4}
=====================
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Whole-genome-SNP-based phylogeny of *E. coli* ST131, including strain AA86 as an outgroup. Phylogeny is based on 4,780 parsimony-informative and 15,978 total SNPs from throughout the genome. Homoplasy index (HI) = 0.351. Download
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Figure S1, PDF file, 0.1 MB
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Whole-genome-SNP-based phylogeny of *E. coli* ST131, excluding strain AA86. Phylogeny is based on 4,770 parsimony-informative and 8,007 total SNPs from throughout the genome. HI = 0.328. Download
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Whole-genome-SNP-based phylogeny of *E. coli* ST131 after removing SNPs from the recombinant regions and including strain AA86 as an outgroup. Phylogeny is based on 2,518 parsimony-informative and 9,533 total SNPs from throughout the genome. HI = 0.044. Download
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Consensus characteristics of the major subclones within the all-ST131 phylogeny.
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Table S1, DOCX file, 0.1 MB.

###### 

Isolate metadata. Download

###### 

Dataset S1, XLSX file, 0.1 MB

###### 

Genetic content of the four recombinant regions excluded for phylogenetic analyses. Download
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